The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells

Molecular and Cellular Biology

Volumn 17, Issue 2, 1997, Pages 713-722

  Almog, Nava ^a   Li, Runzhao ^a   Peled, Amnon ^a   Schwartz, Dov ^a   Wolkowicz, Roland ^a   Goldfinger, Naomi ^a   Pei, Huiping ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; TEMPERATURE SENSITIVE MUTANT;

EID: 0031056054     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.2.713     Document Type: Article

References (85)

1. Alexander, W. S., S. D. Lyman, and E. F. Wagner. 1991. Expression of functional c-kit receptors rescues the genetic defect of the W mutant mast cells. EMBO J. 10:3683-3691.
2. 2-dependent immunoglobulin κ light chain gene expression. EMBO J. 14:1392-1401.
3. Arai, N., U. Nomura, K. Yokota, D. Wolf, E. Brill, O. Shohat, and V. Rotter. 1986. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol. 6:3232-3239.
4. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565-2574.
5. Bayle, J. H., B. Elenbaas, and A. J. Levine. 1995. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA 92: 5729-5733.
6. Belloc, F., P. Dumain, M. R. Boisseau, C. Jalloustre, J. Reiffers, P. Bernard, and F. Lacombe. 1994. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 17:59-65.
7. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
8. Clore, G. M., J. G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, and A. M. Gronenborn. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265:386-394.
9. Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267:1353-1356.
10. Darzynkiewicz, Z., X. Li, and J. Gong. 1994. Assays of cell viability: discrimination of cell dying by apoptosis. Methods Cell Biol. 41:15-38.
11. Diller, L., J. Kassel, C. E. Nelson, M. A. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. J. Baker, B. Vogelstein, and S. H. Friend. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:5772-5781.
12. 1 arrest. Cell 76:1013-1023.
13. Dutta, A., J. M. Ruppert, J. C. Aster, and E. Wincherester. 1993. Inhibition of DNA replication factor RPA by p53. Nature 365:79-82.
14. 2+ associated with apoptosis. Methods Cell Biol. 46: 41-55.
15. El-Deiry, W. S., J. W. Harper, P. M. O'Connor, V. E. Velculescu, C. E. Canman, J. Jackman, J. A. Pietenpol, M. Burrell, D. E. Hill, and Y. Wang. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169-1174.
16. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
17. El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
18. Fields, S., and S. K. Jang. 1990. Presence of potent transcription activating sequences in the p53 protein. Science 249:1046-1049.
19. Flaman, J.-M., F. Waridel, A. Estreicher, A. Vannier, J.-M. Limacher, D. Gilbert, R. Iggo, and T. Frebourg. 1996. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12:813-818.
20. Ford, J. M., and P. C. Hanawalt. 1995. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV-resistance. Proc. Natl. Acad. Sci. USA 92:8876-8890.
21. Gannon, J. V., R. Greaves, R. Iggo, and D. P. Lane. 1990. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1595-1602.
22. Gottlieb, E., R. Haffner, T. von Ruden, E. F. Wagner, and M. Oren. 1994. Down-regulation of wild type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J. 13: 1368-1374.
23. 1 arrest. Blood 85:2691-2698.
24. Han, K., and M. F. Kulesz-Martin. 1992. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucleic Acids Res. 20:1979-1981.
25. Harlow, E., L. V. Crawford, D. C. Pim, and N. M. Williamson. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigen. J. Virol. 39:861-869.
26. Haupt, Y., S. Rowan, E. Shaulian, K. H. Vousden, and M. Oren. 1995. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9:2170-2183.
27. Hunter, T. 1993. Braking the cycle. Cell 75:839-841.
28. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
29. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21:3167-3174.
30. Jayaraman, L., and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021-1029.
31. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
32. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunket, B. Vogelstein, and A. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is detective in ataxia-telangiectasia. Cell 71:587-597.
33. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
34. Kulesz-Martin, M. F., B. Lisafeld, H. Huang, N. D. Kisiel, and L. Lee. 1994. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol. 14:1698-1708.
35. Lane, D. P. 1992. p53, guardian of the genome. Nature 358:15-16.
36. Lee, S., B. Elenbaas, A. Levine, and J. Griffith. 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013-1020.
37. Leveillard, T., L. Andera, N. Bissonnette, L. Schaeffer, L. Bracco, J. Egly, and B. Wasylyk. 1996. Functional interactions between p53 and the THIIH complex are affected by tumour-associated mutations. EMBO J. 15:1615-1624.
38. Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
39. Lu, X., and D. P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing irradiation: defects in chromosome instability syndromes? Cell 75:765-778.
40. Maltzman, W., and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694.
41. Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1120-1124.
42. Mercer, W. E., M. T. Shields, M. Amin, G. J. Sauve, E. Appella, J. W. Romano, and S. J. Ullrich. 1990. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild type p53. Proc. Natl. Acad. Sci. USA 87:6166-6170.
43. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680.
44. Milne, D. M., R. H. Palmer, D. G. Campbell, and D. W. Meek. 1992. Phosphorylation of the p53 tumor-suppressor protein at three N terminal sites by a novel casein-kinase 1-like enzyme. Oncogene 7:1361-1370.
45. Milner, J., E. A. Medcalf, and A. C. Cook. 1991. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11:12-19.
46. Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, and D. A. Liebermann. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805.
47. Okamoto, K., and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:4816-4822.
48. Oltvai, Z. N., and S. J. Korsmeyer. 1994. Checkpoints of dueling dimers foil death wishes. Cell 79:189-192.
49. Oren, M. 1994. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5:221-227.
50. O'Rourke, R. W., C. W. Miller, G. J. Kato, K. J. Simon, D.-L. Chen, C. V. Dang, and H. P. Koeffler. 1990. A potential transcriptional activation element in the p53 protein. Oncogene 5:1829-1832.
51. Pavletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556-2564.
52. Peled, A., B. C. Lee, J. Toledo, M. Aracil, and D. Zipori. 1996. Interactions between leukemia cells and bone marrow stromal cells: stroma-supported growth vs. serum dependence and the roles of TGF-b and M-CSF. Exp. Hematol. 24:728-737.
53. Peled, A., D. Zipori, and V. Rotter. 1996. Cooperation between p53-dependent and p53-independent apoptotic pathways of myeloid cells. Cancer Res. 56:2148-2156.
54. Raycroft, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051.
55. Reed, M., B. Woelker, P. Wang, Y. Wang, M. E. Anderson, and P. Tegtmeyer. 1995. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA 92:9455-9459.
56. Ronen, D., D. Schwartz, Y. Teitz, N. Goldfinger, and V. Rotter. 1996. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild type p53 protein whereas their differentiation is mediated by lower p53 levels. Cell Growth Differ. 7:21-30.
57. Rotter, V., R. Aloni-Grinstein, D. Schwartz, N. B. Elkind, A. Simons, R. Wolkowicz, M. Lavigne, P. Besserman, A. Kapon, and N. Goldfinger. 1994. Does wild type p53 play a role in normal cell differentiation? Semin. Cancer Biol. 5:229-236.
58. Ryan, J. J., R. Danish, C. A. Gotllieb, and M. F. Clarke. 1993. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol. Cell. Biol. 13:711-719.
59. Shaulian. E., I. Haviv, Y. Shaul, and M. Oren. 1994. Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671-680.
60. Shaulsky, G., N. Goldfinger, A. Peled, and V. Rotter. 1991. Involvement of wild type p53 in pre-B cell differentiation in vitro. Proc. Natl. Acad. Sci. USA 88:8982-8986.
61. Shaw, P., J. Freeman, R. Bovey, and R. Iggo. 1996. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12:921-930.
62. Shohat-Foord, O., P. Bhattacharya, Z. Reich, and V. Rotter. 1991. A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res. 19:5191-5198.
63. Slingerland, J. M., J. R. Jenkins, and S. Benchimol. 1993. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J. 12: 1029-1037.
64. Smith, M. L., I.-T. Chen, Q. Zhan, I. Bae, C.-Y. Chen, T. M. Glimer, M. B. Kastan, P. M. O'Connor, and J. A. J. Fornace. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1378.
65. Stewart, N., G. G. Hicks, F. Paraskevas, and M. Mowat. 1994. Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109-115.
66. Tarunina, M., and J. R. Jenkins. 1993. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene 8:3165-317.1
67. Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523-526.
68. 1 cyclin-dependent kinases. Cell 75:805-816.
69. Wang, X. W., K. Forrester, H. Yeh, M. A. Feitelson, J. Gu, and C. Harris. 1994. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA 91:2230-2234.
70. Wang, X. W., W. Vermeulen, J. D. Coursen, M. Gibson, S. E. Lupold, K. Forrester, G. Xu, L. Elmore, H. Yeh, J. H. J. Hoeijmakers, and C. C. Harris. 1996. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 10:1-14.
71. Wang, X. W., H. Yeh, L. Schaeffer, R. Roy, V. Moncolli, J.-M. Egly, Z. Wang, E. C. Friedberg, M. K. Evans, B. G. Taffe, V. A. Bohr, G. Weeda, J. H. J. Hoeijmakers, K. Forrester, and C. C. Harris. 1995. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10:188-195.
72. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2586.
73. Will, K., G. Warnecke, S. Bergmann, and W. Deppert. 1995. Species-and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53. Nucleic Acids Res. 23:4023-4028.
74. Williams. G. T. 1991. Programmed cell death: apoptosis and oncogenesis. Cell 65:1097-1098.
75. Wolf, D., N. Harris, N. Goldfinger, and V. Rotter. 1985. Isolation of full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol. Cell. Biol. 5:127-132.
76. Wolkowicz, R., A. Peled, N. B. Elkind, and V. Rotter. 1995. The augmented DNA binding activity of an alternative spliced C'-terminal p53 is blocked by regular spliced p53 protein. Proc. Natl. Acad. Sci. USA 92:6842-6846.
77. Wu, L., J. H. Bayle, B. Elenbaas, N. P. Pavletich, and A. J. Levine. 1995. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol. 15:497-504.
78. Wu, Y., Y. Liu, L. Lee, Z. Miner, and M. Kulesz-Martin. 1994. Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J. 13:4823-4830.
79. Wyllie, A. H. 1995. The genetic regulation of apoptosis. Curr. Opin. Genet. Dev. 5:97-104.
80. Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:444-452.
81. Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948.
82. Yonish-Rouach, E., V. Deguin, T. Zaitchouk, C. Breugnot, Z. Mishal, J. R. Jenkins, and E. May. 1996. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 12:2197-22115.
83. Yonish-Rouach, E., D. Grunwald, S. Wilder, A. Kimchi, E. May, J.-J. Lawrence, P. May, and M. Oren. 1993. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol. 13:1415-1423.
84. Yonish-Rouach, E., K. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 352:345-347.
85. Zauberman, A., A. Lupo, and M. Oren. 1995. Identification of p53 target genes through immune selection of genoinic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene 10:2361-2366.